SCHEMBL669274

SCHEMBL669274

FC(F)(F)c1ccc(P(Cl)c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
KIF11 P52732 6/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
ORAI1 Q96D31 1/20 0.41
ORAI2 Q96SN7 1/20 0.41
ORAI3 Q9BRQ5 1/20 0.41
TRPV6 Q9H1D0 1/20 0.41
MGLL Q99685 1/20 0.41
TAAR1 Q96RJ0 1/20 0.38
AHR P35869 1/20 0.38
EPHX2 P34913 1/20 0.37
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
PLAU P00749 1/20 0.37
HTR3A P46098 1/20 0.37
HTR3D Q70Z44 1/20 0.37
HTR3C Q8WXA8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201199 0.84 ALDH1A1 (0.43) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL17448527 0.82 ALDH1A1 (0.42) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL669273 0.80 ALDH1A1 (0.40) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL287478 0.78 ALDH1A1 (0.48) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL15661104 0.78 ALDH1A1 (0.48) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL19514107 0.77 ALDH1A1 (0.42) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL63468 0.76 ALDH1A1 (0.67) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL5713308 0.76 ALDH1A1 (0.46) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL31325622 0.76 ALDH1A1 (0.46) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL21724857 0.75 ALDH1A1 (0.40) ALDH1A1TSHRKIF11CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119798332-A Synthesis method and application of quaternary ring near infrared iridium complex based on SS coordination 云南大学 2025-04-11 CN claimed
EP-1598053-B1 Use of a composition containing at least one phosphine as majority reducing agent to remove the artificial colour of keratinic fibres OREAL (FR) 2006-12-20 EP claimed
EP-1598053-A1 Use of a composition containing at least one phosphine as majority reducing agent to remove the artificial colour of keratinic fibres L'OREAL (FR) 2005-11-23 EP claimed
US-20050251928-A1 Method for stripping artificial color from keratin fibers L'OREAL (FR) 2005-11-17 US claimed
US-12319758-B2 Sterically hindered phosphino-urea supported nickel (II) or palladium (II) catalysts for the copolymerization of ethylene and polar comonomers DOW GLOBAL TECHNOLOGIES LLC (US) 2025-06-03 US disclosed
CN-119798332-A Synthesis method and application of quaternary ring near infrared iridium complex based on SS coordination 云南大学 2025-04-11 CN disclosed
CN-119569782-A Hydroformylation catalyst and method for preparing isobutyraldehyde 万华化学集团股份有限公司 2025-03-07 CN disclosed
EP-4126991-B9 STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS DOW GLOBAL TECHNOLOGIES LLC (US) 2025-02-19 EP disclosed
EP-4126991-B1 STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS DOW GLOBAL TECHNOLOGIES LLC (US) 2024-11-27 EP disclosed
CN-115485312-B Sterically hindered phosphino-urea supported nickel (II) or palladium (II) catalysts for the copolymerization of ethylene and polar comonomers 陶氏环球技术有限责任公司 2024-11-19 CN disclosed
US-20240352052-A1 Method for Producing Compound, Compound, and Metal Catalyst JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2024-10-24 US disclosed
CN-114853817-B Iridium complex, organic electroluminescent device and display device 昆山工研院新型平板显示技术中心有限公司 2024-08-23 CN disclosed
US-5481006-A PREPARATION OF INTERMEDIATES FOR PHARMACEUTICALS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1996-01-02 US disclosed
WO-1995018787-A1 SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1995-07-13 WO disclosed
EP-0646590-A1 Ferrocenyldiphosphines substituted with fluoroalkyl groups as ligands for homogeneous catalysis CIBA-GEIGY AG (CH) 1995-04-05 EP disclosed
EP-0605403-A2 Lubricating greases Montedison S.p.A. (IT) 1994-07-06 EP disclosed
US-4472290-A Process for preparing lubricating greases based on polytetrafluoroethylene and perfluoropolyethers MONTEDISON S.P.A. (IT) 1984-09-18 US disclosed
EP-0095825-A2 Process for preparing lubricating greases Montedison S.p.A. (IT) 1983-12-07 EP disclosed
US-4221744-A Hydroformylation process employing rhodium-based catalysts comprising ligands having electronegative substituents CELANESE CORPORATION (US) 1980-09-09 US disclosed
US-4152344-A CATALYSTS FOR HYDROFORMYLATION OF ALPHA-OLEFINS CELANESE CORPORATION (US) 1979-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319758-B2 Sterically hindered phosphino-urea supported nickel (II) or palladium (II) catalysts for the copolymerization of ethylene and polar comonomers PCNA, NIT2, MCM7 ALDH1A1 2942/4885TSHR 3696/4885KIF11 3734/4885
US-20240352052-A1 Method for Producing Compound, Compound, and Metal Catalyst BCL2A1, BCLAF1, BAK1 ALDH1A1 3090/4885TSHR 2873/4885KIF11 3525/4885
US-20050251928-A1 Method for stripping artificial color from keratin fibers KRT18, DSG1, JUP ALDH1A1 4512/4885TSHR 4245/4885KIF11 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.